



Philip Bruggmann

Contact

Philip Bruggmann

Publications (13)

Winter B, Hovaguimian F, Kouyos R, Schmidt A, Bernasconi E, Braun D, Calmy A, Notter J, Stoeckle M, Surial B, Christinet V, Cavassini M, Depmeier C, Läubli S, Boffi El Amari E, Reinacher M, Rasi M, Bruggmann P, Haerry D, Bize R, Low N, Lehner A, Quednow B, Fehr J, Hampel B. Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study. *Swiss Med Wkly* 2022; 152:w30192.

Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batánjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. *Liver Int* 2021

Berendes A, Oeltjenbruns J, Beck T, Bruggmann P. Perioperatives Schmerz-Management unter Buprenorphin-Langzeit-Therapie. *Suchtmedizin* 2021; 23:225-232.

Bobzin C, Semmo N, Semela D, Scheidegger C, Rauch A, Negro F, Moradpour D, Mäschi B, Lavanchy D, Künzler-Heule P, Keiser O, Fraga Christinet M, Cerny A, Bruggmann P, Bösigler C, Thurnheer M. Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. *Swiss Medical Forum* 2021; 21:184-186.

Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer M, Vernazza P, Scheidegger C. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort. *Swiss Med Wkly* 2021; 151:w20460.

Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Mullhaupt B, Negro F, Semela D. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. *Swiss Med Wkly* 2019; 149:w14694.

Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. *PloS one* 2018; 13:e0209374.

Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. *Int J Drug Policy* 2018; 62:94-103.

Marzel A, Kouyos R, Günthard H, Perreau M, Klimkait T, Yerly S, Böni J, Hoffmann M, Cavassini M, Calmy A, Bernasconi E, Roth J, Rauch A, Bruggmann P, Weber R, Kusejko K, Swiss HIV Cohort Study. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. *Open Forum Infect Dis* 2018; 5:ofy078.

Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. *Swiss Med Wkly* 2017; 147:w14543.

Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Mullhaupt B, Razavi H, Semela D. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. *Swiss Med Wkly* 2015; 145:w14221.

Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. *PloS one* 2015; 10:e0125214.

Rasi M, Künzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J, Saxer S, Nicca D. "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. *BMC Infect Dis* 2014; 14:507.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch